Ludwig-Maximilians - University of Munich

lmu.de

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

221

Active

25

Phase 3

21

Total enrollment

81,434

Pipeline matrix

Showing 5 of 5 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Irinotecan7
5-FU6
Folinic Acid5
Panitumumab1
Semaglutide1

Next readouts

  • 2024-08-01
  • 2030-07

Top conditions

  • Depression12
  • Depressive Disorder10
  • Depression in Adolescence9
  • Schizophrenia6
  • Quality of Life5
  • Ischemic Stroke5
  • Metastatic Colorectal Cancer5
  • Healthy5

Frequently asked questions about Ludwig-Maximilians - University of Munich

How many clinical trials does Ludwig-Maximilians - University of Munich have on ClinicalTrials.gov?
Ludwig-Maximilians - University of Munich is listed as the lead sponsor on 221 clinical trials in ClinicalTrials.gov, 25 of which are currently active (recruiting, enrolling, or ongoing).
How many of Ludwig-Maximilians - University of Munich's trials are in Phase 3?
21 of Ludwig-Maximilians - University of Munich's trials are in Phase 3, spread across 5 active drug programs.
What therapeutic areas does Ludwig-Maximilians - University of Munich focus on?
Ludwig-Maximilians - University of Munich's most-studied conditions on ClinicalTrials.gov are Depression, Depressive Disorder, Depression in Adolescence, Schizophrenia, Quality of Life.
When are Ludwig-Maximilians - University of Munich's next clinical trial readouts?
Ludwig-Maximilians - University of Munich has 2 upcoming primary-completion readouts tracked here; the soonest is “Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation”, expected around 2024-08-01.